| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,899,423 ) |
| | 2025 | 2025 | EXTEND BIOSCIENCES INC | 90 BRIDGE ST | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R01FD007824 | A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022) | 000 | 2 | FDA | 6/24/2025 | $899,808 |
| | 2025 | 2025 | EXTEND BIOSCIENCES INC | 90 BRIDGE ST | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R44DK138647 | Long-acting PTH for hypoparathyroidism | 000 | 2 | NIH | 8/8/2025 | $999,615 |
|
| Issue Date FY: 2024 ( Subtotal = $999,615 ) |
| | 2024 | 2024 | EXTEND BIOSCIENCES INC | 90 BRIDGE ST | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R44DK138647 | Long-acting PTH for hypoparathyroidism | 000 | 1 | NIH | 8/29/2024 | $999,615 |
| | 2024 | 2023 | EXTEND BIOSCIENCES INC | 90 BRIDGE ST | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R01FD007824 | A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022) | 000 | 1 | FDA | 10/25/2023 | $0 |
| | 2024 | 2023 | EXTEND BIOSCIENCES INC | 90 BRIDGE ST | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R01FD007824 | A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022) | 002 | 1 | FDA | 9/20/2024 | $0 |
| | 2024 | 2023 | EXTEND BIOSCIENCES INC | 90 BRIDGE ST | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R01FD007824 | A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022) | 002 | 1 | FDA | 9/20/2024 | $0 |
| | 2024 | 2023 | EXTEND BIOSCIENCES INC | 90 BRIDGE ST | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R01FD007824 | A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022) | 000 | 1 | FDA | 10/25/2023 | $0 |
| | 2024 | 2023 | EXTEND BIOSCIENCES INC | 90 BRIDGE ST | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R01FD007824 | A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022) | 003 | 1 | FDA | 9/23/2024 | $0 |
| | 2024 | 2023 | EXTEND BIOSCIENCES INC | 90 BRIDGE ST | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R01FD007824 | A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022) | 003 | 1 | FDA | 9/23/2024 | $0 |
| | 2024 | 2023 | EXTEND BIOSCIENCES INC | 90 BRIDGE ST | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R01FD007824 | A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022) | 001 | 1 | FDA | 9/16/2024 | $0 |
| | 2024 | 2023 | EXTEND BIOSCIENCES INC | 90 BRIDGE ST | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R01FD007824 | A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022) | 001 | 1 | FDA | 9/16/2024 | $0 |
| | 2024 | 2021 | EXTEND BIOSCIENCES INC | 90 BRIDGE ST | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R44DK107231 | Long-acting PTH for hypoparathyroidism | 000 | 5 | NIH | 2/8/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $899,808 ) |
| | 2023 | 2023 | EXTEND BIOSCIENCES INC | 90 BRIDGE ST | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R01FD007824 | A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022) | 000 | 1 | FDA | 9/20/2023 | $2,565 |
| | 2023 | 2023 | EXTEND BIOSCIENCES INC | 90 BRIDGE ST | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R01FD007824 | A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022) | 000 | 1 | FDA | 9/20/2023 | $897,243 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2019 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R43NS115312 | Long-acting ghrelin for neuropathy | 000 | 1 | NIH | 2/14/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,000,000 ) |
| | 2021 | 2021 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R44DK107231 | Long-acting PTH for hypoparathyroidism | 001 | 5 | NIH | 7/22/2021 | $2,000,000 |
| | 2021 | 2020 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R44DK107231 | Long-acting PTH for hypoparathyroidism | 000 | 4 | NIH | 3/25/2021 | $0 |
| | 2021 | 2019 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R43NS115312 | Long-acting ghrelin for neuropathy | 000 | 1 | NIH | 10/14/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,000,000 ) |
| | 2020 | 2020 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R44DK107231 | Long-acting PTH for hypoparathyroidism | 001 | 4 | NIH | 9/12/2020 | $1,000,000 |
| | 2020 | 2018 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R44CA213844 | Long-acting ghrelin for the treatment of cancer cachexia | 000 | 2 | NIH | 9/15/2020 | $0 |
| | 2020 | 2018 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R44DK107231 | Long-acting PTH for hypoparathyroidism | 000 | 3 | NIH | 9/10/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $537,409 ) |
| | 2019 | 2019 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R44CA213844 | Long-acting ghrelin for the treatment of cancer cachexia | 000 | 2 | NIH | 8/14/2019 | $2,084 |
| | 2019 | 2019 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R43NS115312 | Long-acting ghrelin for neuropathy | 000 | 1 | NIH | 9/18/2019 | $535,325 |
| | 2019 | 2018 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R43AI131906 | Long-acting ghrelin for the treatment of ARS | 000 | 2 | NIH | 8/27/2019 | $0 |
| | 2019 | 2017 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R43DK115279 | Ultralong-acting insulin for diabetes | 000 | 1 | NIH | 8/21/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $3,605,077 ) |
| | 2018 | 2018 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R43AI131906 | Long-acting ghrelin for the treatment of ARS | 000 | 2 | NIH | 2/23/2018 | $300,000 |
| | 2018 | 2018 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R44DK107231 | Long-acting PTH for hypoparathyroidism | 000 | 3 | NIH | 7/9/2018 | $1,928,001 |
| | 2018 | 2018 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R44CA213844 | Long-acting ghrelin for the treatment of cancer cachexia | 001 | 2 | NIH | 9/12/2018 | $210,000 |
| | 2018 | 2018 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R44CA213844 | Long-acting ghrelin for the treatment of cancer cachexia | 000 | 2 | NIH | 3/12/2018 | $1,167,076 |
|
| Issue Date FY: 2017 ( Subtotal = $3,285,722 ) |
| | 2017 | 2017 | EXTEND BIOSCIENCES INC. | 700 MAIN ST | CAMBRIDGE | MA | 02139-3543 | MIDDLESEX | USA | R44CA213844 | Long-acting ghrelin for the treatment of cancer cachexia | 000 | 1 | NIH | 4/24/2017 | $832,924 |
| | 2017 | 2017 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R43DK115279 | Ultralong-acting insulin for diabetes | 000 | 1 | NIH | 9/4/2017 | $350,000 |
| | 2017 | 2017 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R44DK107231 | Long-acting PTH for hypoparathyroidism | 000 | 2 | NIH | 9/14/2017 | $1,802,798 |
| | 2017 | 2017 | EXTEND BIOSCIENCES INC. | 700 MAIN ST | CAMBRIDGE | MA | 02139-3543 | MIDDLESEX | USA | R43AI131906 | Long-acting ghrelin for the treatment of ARS | 000 | 1 | NIH | 2/28/2017 | $300,000 |
| | 2017 | 2015 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R43DK107231 | Long acting PTH for hypoparathyroidism | 000 | 1 | NIH | 1/31/2017 | $0 |
| | 2017 | 2014 | EXTEND BIOSCIENCES INC. | 90 BRIDGE ST SUITE 100 | NEWTON | MA | 02458-1119 | MIDDLESEX | USA | R43AA022547 | A Systemically Deliverable RNAi-based Approach for Alcoholic Liver Disease | 000 | 2 | NIH | 2/21/2017 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $306,738 ) |
| | 2015 | 2015 | EXTEND BIOSCIENCES INC | 1 KENDALL SQUARE | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R43DK107231 | Long acting PTH for hypoparathyroidism | 000 | 1 | NIH | 9/24/2015 | $306,738 |
|
| Issue Date FY: 2014 ( Subtotal = $145,500 ) |
| | 2014 | 2014 | EXTEND BIOSCIENCES INC | 1 KENDALL SQUARE | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R43AA022547 | A Systemically Deliverable RNAi-based Approach for Alcoholic Liver Disease | 000 | 2 | NIH | 8/12/2014 | $145,500 |
|
| Issue Date FY: 2013 ( Subtotal = $587,950 ) (Continued on the next page) |
| | 2013 | 2013 | EXTEND BIOSCIENCES INC | 1 KENDALL SQUARE | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R43CA174094 | LONG LASTING GHRELIN DERIVATIVES FOR THE TREATMENT OF CANCER CACHEXIA | 000 | 1 | NIH | 4/29/2013 | $288,302 |
|
